公开(公告)号：US20180305437A1

公开(公告)日：2018-10-25

申请号：US15767801

申请日：2016-10-28

Applicant: AFFIBODY AB

Inventor： Elisabet Wahlberg

IPC: C07K14/705 ,  C07K14/745

CPC classification number: C07K14/70532 ,  A61K38/1774 ,  A61P31/18 ,  A61P31/20 ,  A61P35/02 ,  C07K14/745 ,  C07K2319/00

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERTX4AX6WEIX10X11LPNLX16X17X18QX20GAFIX25X26LHD. The present disclosure also relates to the use of such a PD-L1 binding polypeptide a prognostic and/or diagnostic agent as well as a therapeutic agent.

公开(公告)号：US20220389066A1

公开(公告)日：2022-12-08

申请号：US17771307

申请日：2020-11-05

Applicant: Affibody AB

Inventor： Elisabet Wahlberg

IPC: C07K14/435 ,  C07K19/00

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for high mobility group box 1 protein (HMGB1), and provides an HMGB1 binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20X21AFIYX26LED or a sequence having at least 93% identity thereto. The present disclosure also relates to the use of such an HMGB1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

公开(公告)号：US11155596B2

公开(公告)日：2021-10-26

申请号：US15770956

申请日：2016-10-28

Applicant: AFFIBODY AB

Inventor： Elisabet Wahlberg ,  Elin Gunneriusson

IPC: A61K38/00 ,  C07K14/705 ,  A61K38/16 ,  A61K38/17 ,  A61K38/36 ,  C07K14/745 ,  A61P35/00 ,  A61K47/42 ,  C07K14/47

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. The present disclosure also relates to the use of such a PD-L1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

公开(公告)号：US20180312565A1

公开(公告)日：2018-11-01

申请号：US15770956

申请日：2016-10-28

Applicant: AFFIBODY AB

Inventor： Elisabet Wahlberg ,  Elin Gunneriusson

IPC: C07K14/705 ,  C07K14/47 ,  A61P35/00 ,  A61K47/42

CPC classification number: C07K14/70532 ,  A61K38/00

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. The present disclosure also relates to the use of such a PD-L1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

公开(公告)号：US10364280B2

公开(公告)日：2019-07-30

申请号：US15767801

申请日：2016-10-28

Applicant: AFFIBODY AB

Inventor： Elisabet Wahlberg

IPC: A61K38/17 ,  A61P31/18 ,  A61P31/20 ,  A61P35/02 ,  C07K14/705 ,  C07K14/745

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERTX4AX6WEIX10X11LPNLX16X17X18QX20GAFIX25X26LHD. The present disclosure also relates to the use of such a PD-L1 binding polypeptide a prognostic and/or diagnostic agent as well as a therapeutic agent.